Unveiling the Post-Treatment Reality: What Happens When You Stop Ozempic? | The Jerusalem Post
By DR. DALIT DRAIMAN-MEDINA
JANUARY 12, 2026 17:00
The GLP-1 family of medications, including Ozempic, Wegovy, Saxenda, and Mounjaro, have taken the health world by storm, offering remarkable weight loss, improved blood sugar control, and reduced cardiovascular risks. But as their popularity rises, a critical question emerges: What happens when you discontinue these medications? A recent study published in eClinicalMedicine by The Lancet group sheds light on this very issue, revealing a fundamental limitation of these drugs.
The study, which analyzed 18 randomized clinical trials involving 3,771 participants with obesity, type 2 diabetes, or type 1 diabetes, uncovered a phenomenon known as "metabolic rebound."
The findings were striking. After discontinuing GLP-1 treatment, participants experienced significant weight regain, with an average increase of 5.6 kg in those with obesity. Waist circumference rose by approximately 4 cm, and BMI followed suit. Interestingly, this rebound effect was not limited to obesity; individuals with type 2 diabetes also gained weight, with an average increase of 2 kg.
The study further revealed that the longer the time elapsed since discontinuing treatment, the more pronounced the rebound effect. Moreover, the metabolic improvements achieved during treatment disappeared, leading to a worsening of various health markers.
The culprit behind this phenomenon is the body's natural response to weight loss. When weight loss occurs, the body activates survival mechanisms such as increased hunger hormones, decreased energy expenditure, and a heightened tendency to store fat. GLP-1 medications effectively suppress these mechanisms while they are taken. However, once treatment is stopped, the body reverts to its default state, resulting in the rebound effect.
From a functional medicine perspective, this study's findings are not surprising. GLP-1 medications address symptoms rather than the underlying causes of metabolic issues. They fail to directly address factors like insulin resistance, poor diet quality, lack of sleep and chronic stress, physical inactivity, and microbiome imbalance. When treatment is discontinued, these root causes persist, making the rebound effect almost inevitable.
This doesn't imply that GLP-1 medications are ineffective. On the contrary, they are powerful tools that can significantly improve health for many patients. However, the study emphasizes the need for a comprehensive approach to preserve the benefits. Most individuals will likely require long-term treatment, similar to managing conditions like hypertension or diabetes.
The notion of these medications as a "miracle drug" is challenged by the study's findings. While they offer clear advantages, uncertainties persist regarding lifelong use, long-term risks, and rare side effects. As a result, experts advocate for a cautious, personalized approach, avoiding the expectation of a magic solution.
For patients, the takeaway is not that GLP-1 medications are ineffective. They undoubtedly deliver results. However, the study underscores the importance of a holistic approach to sustainable metabolic health. This includes high-quality nutrition, adequate sleep, stress management, daily physical activity, and support for the digestive system and metabolism. Without addressing these foundational aspects, the rebound effect is likely to occur, leading to the loss of the hard-earned benefits.
In conclusion, this study highlights the chronic nature of obesity and the need for a multi-faceted strategy when using GLP-1 medications. While they are powerful tools, their long-term success hinges on the duration of treatment and addressing the underlying causes of metabolic disorders. As the medical community continues to explore these medications, a balanced perspective is essential, ensuring patients receive the best possible care.
